Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The Evaluate Patient OutComes (ClinicalTrials.gov Identifier: NCT01216072) study was conducted in North America to assess patient- and physician-reported treatment satisfaction in patients with relapsing multiple sclerosis (MS) who received oral fingolimod for 6 months after switching from an injectable disease-modifying therapy (iDMT), without an intervening washout.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Mult Scler Relat Disord

Title: Multiple sclerosis and related disorders

ISSN (Electronic): 2211-0356

ISSN (Print): 2211-0348

Publication date (Electronic): Sep 2014

Volume: 3

Issue: 5

Affiliations

[1 ] Central Texas Neurology Consultants, PA, 16040 Park Valley Drive, Building B, Suite 100, Round Rock, TX 78681, USA. Electronic address: foxtexms@gmail.com.

[2 ] Multiple Sclerosis Center of Northeastern New York, NY, USA. Electronic address: kedwards@tristateneuro.com.

[3 ] Blue Ridge Research Center, VA, USA. Electronic address: brresearch@aol.com.

[4 ] Consultants in Neurology Multiple Sclerosis Center,IL, USA. Electronic address: dwynnmd@gmail.com.

[5 ] North Central Neurology Associates, AL, USA. Electronic address: claganke@prn-inc.net.

[6 ] Multiple Sclerosis Center of Greater Washington, VA, USA. Electronic address: msdoc1@hotmail.com.

[7 ] Advanced Neurosciences Institute, TN, USA. Electronic address: sfhunter@neurosci.us.

[8 ] Meridien Research, FL, USA. Electronic address: chuffman@meridienresearch.net.

[9 ] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Electronic address: edward.kim@novartis.com.

[10 ] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Electronic address: linda.pestreich@novartis.com.

[11 ] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Electronic address: kevin.mccague@novartis.com.

[12 ] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Electronic address: lou.barbato@novartis.com.

Article

Publisher Item ID: S2211-0348(14)00065-0

DOI: 10.1016/j.msard.2014.06.005

PubMed ID: 26265273

SO-VID: 3b80868a-03c5-4d53-bd22-7eba6bd24f7e

History

Keywords: Depression,Fatigue,Fingolimod,Multiple sclerosis,Satisfaction

Data availability:

Keywords: Depression, Fatigue, Fingolimod, Multiple sclerosis, Satisfaction

Comments

Comment on this article

scite_

Cited by 38

See all cited by